Zevalin/Rituxan Has 80% Response Rate In Non-Hodgkin's Lymphoma Patients
Executive Summary
Idec's mouse monoclonal antibody Zevalin in combination with the firm's Rituxan produced an 80% overall response rate in patients with relapsed B-cell non-Hodgkin's lymphoma in an interim analysis of Phase III data presented in a poster May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.